We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The agency said sponsors intending to market multiple dose combinations should “avoid marketing excessive numbers of combinations whose components exert similar blood pressure effects.” Read More
“By approving opioids indicated for the treatment of chronic pain without substantial evidence of their efficacy for this indication, the FDA has helped to facilitate the launch of the U.S. opioid epidemic,” PMRS said. Read More